ImmunoGen shares plummet by 32 after FDA recommends new Phase 3 trial httpbit.ly2w4jJ80Â pharma cancer

ImmunoGen shares plummet by 32% after #FDA recommends new Phase 3 trial http://bit.ly/2w4jJ80  #pharma #cancer

14:15 EDT 16 May 2019 | Pharmafile

ImmunoGen shares plummet by 32% after #FDA recommends new Phase 3 trial http://bit.ly/2w4jJ80  #pharma #cancer

More From BioPortfolio on "ImmunoGen shares plummet by 32% after #FDA recommends new Phase 3 trial http://bit.ly/2w4jJ80  #pharma #cancer"